If you’re interested in buying some exchange traded funds (ETFs), then the two listed below could be worth considering.

Here’s what you need to know about these ETFs:

BetaShares Global Cybersecurity ETF (ASX: HACK)

The first ETF for investors to consider is the BetaShares Global Cybersecurity ETF. This ETF gives investors exposure to the growing cybersecurity sector.

With more and more infrastructure and services shifting to the cloud, online threats are only getting greater. This is expected to lead to demand for cybersecurity services continuing to increase for years to come.

This will be good news for the shares included in the BetaShares Global Cybersecurity ETF, which include the leaders in the global cybersecurity sector. These are the likes of Accenture, Cisco, Cloudflare, Crowdstrike, and Okta.

VanEck Vectors MSCI World ex Australia Quality ETF (ASX: QUAL)

Another ETF that could be worth a look is the VanEck Vectors MSCI World ex Australia Quality ETF.

This ETF gives investors exposure to a high quality group of shares from share markets across the world. And as it excludes Australian shares, it could be a good option for investors that are already overweight with ASX investments.

VanEck notes that to be included in the fund, companies need to pass certain criteria. This includes having low leverage, high earnings growth rates, and high returns on equity. Among its holdings are giants such as Apple, Microsoft, Nike, and Nvidia.

Felicity Thomas from Shaw and Partners is a fan of this ETF. She recent told Livewire: “[F]or me, it’s actually a buy. With rising interest rates and the war that’s going on in Europe, I actually think it’s important to invest in quality companies with high revenue growth and a solid balance sheet, which QUAL provides.”

The post 2 high quality ETFs for ASX investors to buy appeared first on The Motley Fool Australia.

More reading

• Here are 2 ASX-listed ETFs that might be able to fend off inflation
• Here are 2 quality ETFs that are now a lot cheaper
• Here are 2 ETFs delivering breakneck ASX performance
• 2 excellent ETFs for investors to buy in May
• 3 top ETFs for ASX investors to buy and hold for 10 years

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended BETA CYBER ETF UNITS. The Motley Fool Australia has positions in and has recommended BETA CYBER ETF UNITS. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/LvPRJaG

Fortunately for growth investors, there are plenty of shares on the Australian share market with strong long term growth potential.

Two such shares that have been named as buys are named below. Here’s why analysts are positive on them:

NextDC Ltd (ASX: NXT)

The first growth share that could be a buy is NextDC. It is a leading data centre operator which appears well-placed to benefit from the structural shift to the cloud.

Especially given the company’s world class network of centres across key locations throughout Australia.

In addition, NextDC has its eyes on edge centres (regional data centres) and the Asia market. The latter has seen the company open up offices in Singapore and Tokyo. These markets could provide NEXTDC with a long growth runway.

Citi is a fan and is forecasting strong earnings growth over the coming years. As a result, it currently has a buy rating and $14.55 price target on NEXTDC’s shares.

Xero Limited (ASX: XRO)

Another ASX growth to look at is Xero. It is a cloud-based accounting solution platform provider to small and medium sized businesses globally.

Xero has been growing at a rapid rate in recent years and continued this trend in FY 2022. Earlier this month, the company released its full-year results and revealed a 29% increase in revenue to NZ$1.1 billion and a 28% jump in annualised monthly recurring revenue (AMRR) to NZ$1.2 billion. This was underpinned by a 19% increase in total subscribers to 3.3 million thanks to growth in all markets.

Positively, Xero’s subscriber count is still well short of its total addressable market of 45 million subscribers globally. This and its plan to monetise its growing user base give it a very long growth runway in the 2020s.

Goldman Sachs is bullish on Xero and believes it has a multi-decade growth runway. Its analysts currently have a buy rating and $118.00 price target on its shares.

The post Analysts name 2 ASX growth shares to buy now appeared first on The Motley Fool Australia.

More reading

• What’s happening with ASX 200 tech shares today?
• Why this ASX 200 share is my biggest personal holding: fund manager
• 2 beaten down ASX tech shares analysts say have major upside potential
• Leading brokers name 3 ASX shares to sell today
• Why this fund manager is backing Xero shares for the rest of 2022

Motley Fool contributor James Mickleboro owns NEXTDC Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/wWshKlc

Today, the S&P/ASX 200 Index (ASX: XJO) followed Wall Street off the edge of a cliff. Investors exited retailers amid concerns of earnings pressure from inflation after a disappointing first quarter result from Target. At the end of the session, the benchmark index finished 1.65% lower at 7,064.5 points.

To the disappointment of shareholders, there were minimal glimmers of green in the Australian share market today. The sole sector managing to catch a bid and stay above the red sea was healthcare. Meanwhile, the rest of the index felt the pain of pessimism on Thursday.

In a rare sight to see, consumer staples fell more than tech. The sector, which is typically considered more stable, was trodden on amid concerns the broader retail sector could be adversely affected by inflation.

However, the question is: which shares delivered the biggest returns to investors on the ASX today? Here are the top ten stocks that came through for investors:

Top 10 ASX shares countdown today

Looking at the top 200 listed companies, Aristocrat Leisure Ltd (ASX: ALL) was the biggest gainer today. Shares in the gaming technology company jumped 6.74% after publishing cracking half year results and announcing a $500 million share buyback. Find out more about Aristocrat Leisure here.

The next best performing ASX share across the market today was Evolution Mining Ltd (ASX: EVN). The gold miner moved 2.04% ahead as the gold price inched higher in the last 24 hours. Uncover the latest Evolution Mining details here.

Today’s top 10 biggest gains were made in these ASX shares:

ASX-listed company	Share price	Price change
Aristocrat Leisure Ltd (ASX: ALL)	$33.73	6.74%
Evolution Mining Ltd (ASX: EVN)	$3.50	2.04%
Genesis Energy Ltd (ASX: GNE)	$2.46	1.65%
Northern Star Resources Ltd (ASX: NST)	$8.71	1.63%
Webjet Ltd (ASX: WEB)	$5.87	1.38%
Pro Medicus Ltd (ASX: PME)	$40.76	1.32%
Skycity Entertainment Group Ltd (ASX: SKC)	$2.54	1.20%
Meridian Energy Ltd (ASX: MEZ)	$4.21	0.96%
Challenger Ltd (ASX: CGF)	$7.47	0.81%
Ebos Group Ltd (ASX: EBO)	$35.28	0.77%

Our top 10 ASX shares today countdown is a recurring end-of-day summary to ensure you know which companies were making big moves on the day. Check-in at Fool.com.au after the market has closed during weekdays to see which stocks make the countdown.

The post Here are the top 10 ASX shares today appeared first on The Motley Fool Australia.

More reading

• Has the ANZ dividend been growing?
• These 3 shares are topping the ASX 200 volume charts on Thursday
• 3 ASX 200 shares defying today’s carnage to climb higher
• Why Aristocrat, Arafura, Calix, and Strike Energy shares are charging higher
• Zip share price dives to yet another multi-year low

Motley Fool contributor Mitchell Lawler has positions in Pro Medicus Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Pro Medicus Ltd. The Motley Fool Australia has positions in and has recommended Pro Medicus Ltd. The Motley Fool Australia has recommended Challenger Limited and Webjet Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/wGJ9bUs

The Imugene Limited (ASX: IMU) share price took off today despite the company’s silence.

However, today’s gains might have been a belated reaction to the news the company announced to the ASX yesterday.

As of Thursday’s close, the Imugene share price is 20 cents. That’s 17.65% higher than it was at the end of Wednesday’s session. It reached an intraday high of 21.5 cents today, representing a 26.47% gain.

For context, the S&P/ASX 200 Index (ASX: XJO) finished the day 1.6% lower.

Let’s take a closer look at the latest news from the clinical-stage immuno-oncology company.

Did this drive the Imugene share price today?

The Imugene share price leapt higher today as the healthcare sector outperformed.

In fact, the stock’s sector, represented by the S&P/ASX 200 Health Care Index (ASX: XHJ), was the only one in the green today. It closed 0.1% higher and was, perhaps unsurprisingly, led by Imugene.

The stock’s movement comes one day after the company announced the first patient has been dosed in its phase 1 clinical trial of its cancer-killing oncolytic virus CF33-hNIS, Vaxinia.

The trial is the first time the virus has come up against tumours in humans.

It has previously been shown to shrink colon, lung, breast, ovarian, and pancreatic cancer tumours in preclinical laboratory and animal models.

The study is being run in partnership with City of Hope. That’s the cancer treatment and research organisation that developed the virus. The study aims to recruit 100 patients across Australia and the United States.

The Imugene share price gained 3% yesterday. Though, the stock has notably underperformed throughout 2022 so far.

It is 53% lower than it was at the start of 2022. It has also fallen 50% since this time last year.

The post Imugene share price surges 18% to lead the ASX 200 on Thursday appeared first on The Motley Fool Australia.

More reading

• 2 ASX All Ordinaries shares having a cracking day, despite the carnage
• ASX 200 midday update: Aristocrat’s earnings beat, Webjet flops, retailers smashed
• Here’s why the Imugene share price just got a boost
• Why Imugene, Integrated Research, Monash IVF, and Step One shares are sinking
• ASX 200 midday update: Brambles rockets, Goodman upgrades guidance

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/hx9Miks